BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information Letter on Tasigna®

2009.09.15

Active substance: nilotinib

The Federal Institute for Drugs and Medical Devices (BfArM) requests consideration of the Information letter concerning the medicinal product Tasigna®

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 770KB, File does not meet accessibility standards